Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

Shares of AbbVie (NYSE:ABBV) hit a session low on Tuesday as Reuters reported that UnitedHealth (NYSE:UNH) is removing the company's blockbuster therapy Humira from some of its formulary lists for ...

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market. Sales of AbbVie’s Humira (adalimumab ...

AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses ...

Read the Medication Guide and Instructions for Use provided by your pharmacist before you start using adalimumab and each time you get a refill. Ask your health care professional how to prepare ...

Opens in a new tab or window Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Alvotech (ALVO), a commercial-stage global biotech company specializing in the development and manufacture of biosimilar medicines, ...

The company's immunology portfolio, particularly Skyrizi and Rinvoq, has been a key driver of growth, helping to offset the anticipated decline in Humira sales due to biosimilar competition.

The use of biologic-based therapeutics has revolutionized our ability to treat complex diseases such as cancer- and autoimmune-related disorders. Biologic-based therapeutics are known to generate anti ...